The Complete Guide to Exercise Mimetic Peptides: SLU-PP-332 and MOTS-c in Metabolic Research (2026)

Introduction: The Quest for Exercise in a Pill

For decades, the scientific community has pursued one of the most ambitious goals in metabolic research: replicating the profound, multi-system benefits of physical exercise through pharmacological intervention. Exercise remains the single most effective “medicine” known to science — it reduces the risk of cardiovascular disease, type 2 diabetes, neurodegenerative disorders, certain cancers, and all-cause mortality. Yet a staggering portion of the global population remains sedentary. The World Health Organization estimates that approximately 1.4 billion adults worldwide are insufficiently active, contributing to an annual economic burden exceeding $54 billion in direct healthcare costs alone.

This reality has driven researchers to ask a provocative question: what if we could activate the molecular pathways triggered by exercise without the exercise itself? The answer lies in a class of compounds known as exercise mimetic peptides — molecules capable of engaging the same signaling cascades, transcriptional programs, and metabolic adaptations that physical activity initiates at the cellular level.

Among the most promising exercise mimetic compounds to emerge in recent years are SLU-PP-332, a small-molecule agonist of estrogen-related receptors (ERRs), and MOTS-c, a mitochondrial-derived peptide that activates AMP-activated protein kinase (AMPK) and regulates systemic metabolism. Both compounds have generated extraordinary interest within the research community — SLU-PP-332 for its ability to induce a 12% reduction in body weight in obese mice without changes in food intake or physical activity, and MOTS-c for its unique origin within mitochondrial DNA and its capacity to improve insulin sensitivity and exercise tolerance even in aged organisms.

This guide represents the most comprehensive resource available on exercise mimetic peptides as of 2026. We will examine the molecular mechanisms, preclinical evidence, comparative pharmacology, and future research directions for both SLU-PP-332 and MOTS-c, situating them within the broader landscape of exercise mimetic science.

What Are Exercise Mimetic Compounds?

An exercise mimetic is any compound — small molecule, peptide, or biologic — that activates one or more of the molecular pathways normally engaged by physical exercise. The term was popularized following landmark research by Ronald Evans and colleagues at the Salk Institute, who demonstrated in 2008 that the PPAR? agonist GW501516, when combined with the AMPK activator AICAR, could dramatically enhance endurance capacity in sedentary mice (Narkar et al., 2008).

To understand why exercise mimetics are so scientifically compelling, it helps to appreciate what exercise actually does at the molecular level. A single bout of moderate-intensity aerobic exercise triggers:

• AMPK activation — sensing the drop in cellular ATP:AMP ratio, AMPK initiates catabolic pathways including fatty acid oxidation and glucose uptake
• PGC-1? upregulation — the “master regulator” of mitochondrial biogenesis is transcriptionally induced
• ERR activation — estrogen-related receptors ?, ?, and ? coordinate the expression of genes involved in oxidative metabolism
• mTOR modulation — mechanistic target of rapamycin signaling is acutely suppressed during exercise but activated during recovery
• Myokine release — skeletal muscle secretes hundreds of signaling molecules (irisin, IL-6, BDNF, meteorin-like)
• Mitochondrial dynamics — fusion, fission, and mitophagy are coordinated to optimize mitochondrial network function
• Epigenetic remodeling — DNA methylation, histone modifications, and microRNA profiles shift in response to contractile activity

The challenge — and the opportunity — is that no single compound can replicate all of these effects simultaneously. Instead, exercise mimetics target specific nodes within this vast signaling network. SLU-PP-332 targets the ERR transcriptional axis, while MOTS-c engages the AMPK-mediated metabolic sensing pathway.

The Ideal Exercise Mimetic: What Researchers Are Looking For

The “perfect” exercise mimetic compound would reproduce the full spectrum of exercise adaptations. In practice, researchers evaluate candidates based on several key criteria:

1. Target specificity — Does the compound activate a well-characterized exercise-responsive pathway?
2. Metabolic efficacy — Does it alter body composition, glucose homeostasis, or lipid metabolism?
3. Muscle phenotype effects — Does it induce fiber-type switching, mitochondrial biogenesis, or endurance enhancement?
4. Safety profile — What are the off-target effects, and is the therapeutic window acceptable?
5. Translatability — Are the mechanisms conserved across species?

SLU-PP-332: The ERR Agonist That Made Headlines

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptor (ERR) family, developed by a research team led by Thomas Burris and colleagues at Washington University in St. Louis. First described in detail in a 2023 publication in the Journal of Medicinal Chemistry, SLU-PP-332 quickly became the subject of widespread scientific and media attention.

Understanding the ERR Family: The Transcriptional Heart of Exercise Adaptation

The estrogen-related receptors — ERR?, ERR?, and ERR? — are orphan nuclear receptors that, despite their name, do not bind estrogen. Instead, they function as constitutively active transcription factors regulating genes involved in oxidative metabolism, mitochondrial function, and energy homeostasis.

ERR? is the most widely expressed isoform, particularly abundant in tissues with high energy demands: skeletal muscle, heart, kidney, and brown adipose tissue. ERR? directly regulates genes encoding enzymes of fatty acid oxidation (CPT1B, MCAD, VLCAD), the tricarboxylic acid cycle (IDH3A, SDH), and the electron transport chain (NDUFS1, COX5A, ATP5A1).

ERR? is enriched in oxidative (type I) muscle fibers and plays a non-redundant role in specifying the slow-twitch, fatigue-resistant muscle phenotype. Rangwala and colleagues (2010) demonstrated that transgenic overexpression of ERR? in mouse skeletal muscle converted glycolytic fibers to an oxidative phenotype, dramatically enhancing endurance running capacity.

Mechanism of Action: How SLU-PP-332 Works

SLU-PP-332 functions as a pan-ERR agonist, activating all three receptor isoforms. The compound binds to the ligand-binding domain (LBD) of the ERRs, stabilizing the receptor in an active conformation that promotes coactivator recruitment and transcriptional activation. The downstream effects include:

• Upregulation of fatty acid oxidation genes — Increased expression of CPT1B, the rate-limiting enzyme for mitochondrial fatty acid import
• Enhanced mitochondrial biogenesis — Induction of TFAM, NRF1, and components of the electron transport chain
• Muscle fiber-type specification — Promotion of the oxidative (type I/IIa) fiber phenotype through ERR?-dependent gene programs
• Increased energy expenditure — Through enhanced mitochondrial oxidative capacity and substrate utilization
• Improved glucose homeostasis — Enhanced insulin-independent glucose uptake in muscle through GLUT4 translocation

The Landmark Mouse Studies: 12% Weight Loss Without Exercise

The study that propelled SLU-PP-332 into the spotlight demonstrated that administration to diet-induced obese (DIO) mice resulted in a 12% reduction in body weight — without any changes in food intake, caloric restriction, or physical activity levels. Key findings:

• Body composition: Significant reductions in fat mass, particularly visceral adipose tissue, while lean mass was preserved
• Endurance capacity: Treated mice ran approximately 50-70% farther on treadmill endurance tests
• Metabolic parameters: Fasting glucose, insulin levels, and triglycerides were all improved
• Muscle phenotype: Histological analysis revealed a shift toward oxidative fiber types with elevated mitochondrial DNA copy number
• Gene expression: RNA-seq confirmed robust upregulation of ERR target genes involved in fatty acid oxidation and oxidative phosphorylation

The weight loss was achieved without the gastrointestinal side effects commonly associated with GLP-1 receptor agonists such as semaglutide or retatrutide. While those compounds reduce body weight primarily through appetite suppression, SLU-PP-332 works by increasing metabolic rate and fat oxidation — a fundamentally different mechanism.

MOTS-c: The Mitochondrial-Derived Peptide Rewriting Metabolic Science

If SLU-PP-332 represents the pharmacological approach to exercise mimicry, then MOTS-c represents nature’s own exercise mimetic — an endogenous peptide produced by the cell’s own mitochondria that orchestrates metabolic adaptation across multiple organ systems.

Mitochondrial-Derived Peptides: A New Class of Signaling Molecules

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) was discovered in 2015 by Changhan Lee and colleagues at the University of Southern California (Lee et al., 2015). It is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene — a region previously thought to serve only structural functions.

MOTS-c belongs to the broader family of mitochondrial-derived peptides (MDPs), which also includes humanin and SHLP1-6. These peptides function as retrograde signals — messages sent from mitochondria to the nucleus to coordinate metabolic homeostasis.

Mechanism of Action: AMPK Activation and Beyond

MOTS-c activates AMPK through a unique mechanism involving disruption of the de novo purine biosynthesis pathway. Specifically, MOTS-c inhibits the folate cycle at the level of ATIC, leading to accumulation of the metabolite AICAR — itself a well-known AMPK activator (Lee et al., 2015). The downstream consequences include:

• Enhanced fatty acid oxidation — AMPK phosphorylates and inactivates ACC, reducing malonyl-CoA levels and relieving inhibition of CPT1
• Increased glucose uptake — AMPK promotes GLUT4 translocation, increasing insulin-independent glucose uptake
• Inhibition of lipogenesis — AMPK suppresses SREBP1c and other lipogenic transcription factors
• Mitochondrial biogenesis — AMPK activates PGC-1? through direct phosphorylation and deacetylation
• Autophagy induction — AMPK activates ULK1 to initiate cellular recycling
• mTORC1 inhibition — AMPK phosphorylates TSC2 and Raptor to suppress anabolic signaling

Nuclear Translocation: MOTS-c as a Transcriptional Regulator

A groundbreaking 2020 study by Kim et al. revealed that under conditions of metabolic stress, MOTS-c translocates from mitochondria into the nucleus, where it directly regulates gene expression. Using ChIP-seq, the researchers demonstrated that nuclear MOTS-c binds to promoter regions of genes involved in antioxidant defense (NRF2/ARE pathway). This was paradigm-shifting — establishing that a mitochondrial-encoded peptide could function as a direct transcriptional regulator.

Key Preclinical Findings with MOTS-c

Obesity and Metabolic Syndrome: Lee et al. (2015) demonstrated that MOTS-c administration prevented diet-induced obesity in mice, with reduced weight gain, improved glucose tolerance, and lower fasting insulin — without changes in food intake.

Age-Related Metabolic Decline: Reynolds et al. (2021) showed that MOTS-c levels decline with aging and that exogenous administration in old mice could restore exercise capacity and improve physical performance.

Exercise Enhancement: D’Souza et al. (2020) reported that endogenous MOTS-c levels rise acutely during exercise in humans, establishing a direct physiological link between physical activity and MOTS-c biology.

Bone Health: Ming et al. (2016) demonstrated that MOTS-c promotes osteoblast differentiation through AMPK-dependent mechanisms.

SLU-PP-332 vs MOTS-c: Head-to-Head Comparison

Parameter	SLU-PP-332	MOTS-c
Compound Type	Synthetic small molecule	Endogenous mitochondrial-derived peptide
Primary Target	ERR?, ERR?, ERR? (pan-ERR agonist)	AMPK activation via folate/purine cycle
Weight Loss in DIO Mice	~12% body weight reduction	Significant prevention of weight gain
Effect on Food Intake	No change	No change
Endurance Enhancement	50-70% increase in running distance	Significant, especially in aged models
Muscle Fiber Effects	Promotes type I/IIa oxidative fiber conversion	Enhances oxidative capacity within fibers
Mitochondrial Biogenesis	Strong (direct ERR-PGC-1? axis)	Moderate (indirect via AMPK-PGC-1?)
Anti-Aging Data	Limited	Strong (reverses age-related decline)
Endogenous?	No (synthetic)	Yes — exercise-regulated
Research Availability	Proxiva Labs	Proxiva Labs

The Broader Exercise Mimetic Landscape

AICAR (Acadesine)

AICAR was one of the first exercise mimetics. Narkar et al. (2008) demonstrated that AICAR treatment increased running endurance by approximately 44% in sedentary mice. However, AICAR has poor oral bioavailability, activates AMPK ubiquitously, and has inconsistent body composition effects. MOTS-c works partly through the same pathway but may engage AMPK in a more physiologically nuanced manner.

GW501516 (Cardarine)

GW501516 is a PPAR? agonist that showed dramatic exercise-mimetic effects but was abandoned after long-term carcinogenicity studies revealed tumor development in multiple organ systems. SLU-PP-332 and MOTS-c target different pathways without the same toxicological profile.

Compound	Primary Target	Endurance Effect	Weight Loss	Safety Concerns
SLU-PP-332	ERR?/? agonism	Strong (50-70%?)	12% in DIO mice	Low (preclinical)
MOTS-c	AMPK (via folate cycle)	Moderate-Strong	Significant	Low (endogenous)
AICAR	AMPK (direct)	Moderate (44%?)	Inconsistent	Moderate
GW501516	PPAR? agonism	Very Strong	Strong	High (carcinogenicity)

Metabolic Pathways and Fat Oxidation: The Molecular Details

Fatty Acid Oxidation: The Central Pathway

The breakdown of stored triglycerides involves lipolysis, fatty acid transport, and mitochondrial ?-oxidation. The rate-limiting step is CPT1 activity, regulated by malonyl-CoA. Both SLU-PP-332 and MOTS-c reduce the malonyl-CoA brake on CPT1 through different mechanisms:

• SLU-PP-332 increases transcription of CPT1B itself through ERR-mediated gene expression
• MOTS-c activates AMPK, which phosphorylates and inhibits ACC, dropping malonyl-CoA levels

Mitochondrial Biogenesis: Building More Engines

The master regulator PGC-1? drives mitochondrial gene expression. SLU-PP-332 provides activated ERR “partners” for PGC-1?, while MOTS-c phosphorylates and activates PGC-1? through AMPK. The two mechanisms are complementary — one amplifies the transcriptional output, the other amplifies the coactivator input.

Thermogenesis and Energy Dissipation

Brown and beige adipose tissues express UCP1, which uncouples the mitochondrial proton gradient from ATP synthesis, dissipating energy as heat. ERR activation by SLU-PP-332 may contribute to thermogenesis through several routes. ERR? and ERR? are expressed in brown adipose tissue and regulate UCP1 expression. The increased mitochondrial density in muscle tissue also creates substrate for “futile cycling” — metabolic processes that consume ATP without productive work.

Exercise Mimetics and Muscle Biology

Fiber-Type Switching and the Oxidative Phenotype

SLU-PP-332’s activation of ERR? promotes the slow-twitch muscle program. Transgenic mice overexpressing ERR? display near-complete type I fiber conversion, doubled running distance, and obesity resistance (Rangwala et al., 2010). SLU-PP-332 pharmacologically recapitulates elements of this phenotype.

Sarcopenia and Age-Related Muscle Loss

Sarcopenia affects approximately 10-16% of the elderly population and is associated with falls, fractures, disability, and increased mortality. MOTS-c is particularly compelling because endogenous levels decline with aging (Kim et al., 2018). Exogenous administration in aged mice restores exercise capacity and metabolic parameters, effectively “rejuvenating” old muscle metabolism (Reynolds et al., 2021).

Muscle as an Endocrine Organ

Contracting muscle releases hundreds of myokines that exert beneficial effects on distant organs — brain (BDNF), bone (IL-6), adipose tissue (irisin), and liver (FGF21). Any compound that enhances the “exercised” phenotype of muscle tissue may augment its secretory profile, producing systemic benefits beyond the muscle itself.

Potential Research Applications

Obesity and Metabolic Syndrome Research

Both compounds reduce body weight through increased energy expenditure rather than appetite suppression — fundamentally different from GLP-1 receptor agonists like semaglutide and tri-agonists like retatrutide. Combination approaches pairing appetite-suppressing agents with energy expenditure-enhancing exercise mimetics are an active area of investigation.

Type 2 Diabetes and Insulin Resistance

MOTS-c’s AMPK-mediated enhancement of glucose uptake in skeletal muscle is particularly relevant, as skeletal muscle handles approximately 80% of insulin-stimulated glucose disposal.

Cardiovascular Research

ERR signaling is critical for cardiac metabolism — the heart relies on fatty acid oxidation for approximately 70% of its ATP. Whether SLU-PP-332’s pan-ERR agonism could support cardiac function in heart failure models is an intriguing research question.

Neurodegenerative Disease

Exercise is neuroprotective, reducing the risk of Alzheimer’s, Parkinson’s, and cognitive decline. MOTS-c’s ability to enhance mitochondrial function and activate AMPK positions it as a candidate for neuroprotection research.

Healthy Aging and Longevity

MOTS-c’s decline with aging and its ability to restore youthful metabolic function in old animals make it a compelling candidate for aging research. The metabolic reprogramming induced by SLU-PP-332 aligns with observations that caloric efficiency declines in long-lived organisms.

Stacking Considerations for Researchers

SLU-PP-332 + MOTS-c: Mechanistic Rationale

The combination engages two critical nodes in the exercise signaling network. SLU-PP-332 provides activated nuclear receptor partners for PGC-1?, while MOTS-c phosphorylates and activates PGC-1? itself. The predicted result is synergistic enhancement of mitochondrial biogenesis exceeding what either compound achieves alone.

Non-overlapping downstream effects that could be additive:

• SLU-PP-332 uniquely drives fiber-type switching toward the oxidative phenotype
• MOTS-c uniquely activates autophagy through AMPK-ULK1
• MOTS-c uniquely engages nuclear NRF2/ARE antioxidant defense programs
• SLU-PP-332 uniquely upregulates transcriptional capacity for mitochondrial gene expression

Exercise Mimetics + Metabolic Peptides

AOD 9604, a modified fragment of human growth hormone, could mobilize fatty acids from adipose stores, while SLU-PP-332 or MOTS-c would enhance oxidative capacity to burn those mobilized fatty acids — a sequential “release and burn” approach to fat reduction research.

Current Research Limitations and Future Directions

Limitations of Current Evidence

Species translation: Most data comes from rodent models. Mice differ from humans in metabolic rate, body composition, and drug pharmacokinetics.

Long-term safety: While MOTS-c benefits from its endogenous nature, effects of supraphysiological dosing over extended periods remain unknown. SLU-PP-332 requires comprehensive toxicological evaluation.

Exercise complexity: No single compound can fully replicate the hundreds of molecular pathways engaged by physical exercise. Exercise mimetics should be viewed as tools for activating specific pathways, not replacements for physical activity.

Emerging Research Directions

Combination with exercise: Rather than replacing physical activity, these compounds might amplify exercise-induced adaptations — a “more gain from the same pain” paradigm.

Sex-specific effects: ERR biology differs between males and females, and most preclinical studies have used male mice.

Biomarker development: Identifying circulating biomarkers that track exercise mimetic efficacy would facilitate research translation.

Structural optimization: Medicinal chemistry efforts seek next-generation compounds with improved potency, selectivity, and oral bioavailability.

Microbiome interactions: Whether exercise mimetics produce similar microbiome effects as exercise represents a largely unexplored frontier.

Conclusion

The field of exercise mimetic research stands at a genuinely transformative moment. SLU-PP-332 offers a direct route to enhanced mitochondrial biogenesis, oxidative fiber-type switching, and increased energy expenditure — producing 12% weight loss in obese mice without exercise. MOTS-c engages the AMPK-PGC-1? axis to improve insulin sensitivity, enhance exercise capacity, and reverse age-related metabolic decline with the elegance of an endogenous molecule.

Together, these compounds illuminate the possibility of a future in which the metabolic benefits of exercise can be augmented, enhanced, or partially replicated through targeted pharmacological intervention. The implications for obesity, diabetes, sarcopenia, cardiovascular disease, neurodegeneration, and aging research are profound.

As we move through 2026 and beyond, the continued investigation of SLU-PP-332, MOTS-c, and their potential combinations will undoubtedly yield discoveries that reshape our understanding of metabolism, muscle biology, and human health. The exercise pill may not yet be here — but the science has never been closer.

References

1. Narkar VA, Downes M, Yu RT, et al. AMPK and PPAR? agonists are exercise mimetics. Cell. 2008;134(3):405-415.
2. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
3. Kim SJ, Mehta HH, Wan J, et al. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging. 2018;10(6):1239-1256.
4. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metabolism. 2020;32(6):1046-1056.
5. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Nature Communications. 2021;12(1):470.
6. Rangwala SM, Wang X, Calvo JA, et al. Estrogen-related receptor ? is a key regulator of muscle mitochondrial activity. Journal of Biological Chemistry. 2010;285(29):22619-22629.
7. Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPAR?. PLoS Biology. 2004;2(10):e294.
8. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-?-dependent myokine that drives brown-fat-like development of white fat. Nature. 2012;481(7382):463-468.
9. Ming W, Lu G, Xin S, et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016;476(4):412-419.
10. Fan W, Evans RM. Exercise mimetics: impact on health and performance. Cell Metabolism. 2017;25(2):242-247.

This article is for educational and research purposes only. Not intended as medical advice. All compounds discussed are for laboratory research use. Visit Proxiva Labs for verified research peptides.